Brief: Helixmith Announces 50% Enrollment In Its Clinical Trial For COVID-19, Involving Tadios
01/12/2021 11:21
Dec 1 (Reuters) - Helixmith Co Ltd 084990.KQ :
* HELIXMITH ANNOUNCES 50% ENROLLMENT IN ITS CLINICAL TRIAL
FOR
COVID-19, INVOLVING TADIOS
* HELIXMITH CO LTD - ONGOING TADIOS CLINICAL TRIAL IS BEING
CONDUCTED IN FOUR TRIAL SITES
* HELIXMITH - TADIOS APPEARS TO PREVENT OR INHIBIT DISEASE
PROGRESSION UPON VIRAL INFECTION THROUGH A REDUCTION OF
INFLAMMATORY AND OXIDATIVE RESPONSE
Source text for Eikon: ID:nPncbKhjja
Further company coverage: 084990.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Helixmith
See all newsBrief: Helixmith Announces Topline Results From Double-Blind Placebo Controlled Multicenter Study For TADIOS Involving 100 Subjects Infected With COVID-19
Brief: Helixmith Announces 50% Enrollment In Its Clinical Trial For COVID-19, Involving Tadios
Brief: ViroMed issues 2nd series convertible bonds worth 100 bln won
Brief: ViroMed appoints CEO
Brief: ViroMed receives patent